How Much Does Farxiga Cost? Government Prices, Generic Approvals and What Moves Your Price

Quick answer

As of September 2026, the federal TrumpRx page for Farxiga (dapagliflozin) prints a "Trump Rx Price" of $35.00 for a 30-count bottle of tablets, against an "Original Price" of $377.82, and describes that figure as an out-of-pocket price for people ordering directly from the manufacturer. That is one of three government-published numbers that frame what Farxiga costs as of September 2026: the TrumpRx price, the Medicare negotiated price of $178.50 for a 30-day supply that took effect on January 1, 2026, and the FDA approval of 19 generic dapagliflozin applications on April 6, 2026. What any one person pays depends on insurance, deductible stage, brand versus generic, the pharmacy and program eligibility.

What does Farxiga cost on TrumpRx?

TrumpRx.gov is a federal website that lists prescription medicines at what it calls Most-Favored-Nation pricing. Its Farxiga page, read live on September 22, 2026, prints an Original Price of $377.82, a savings line of $342.82 and a Trump Rx Price of $35.00 for a 30-count bottle of tablets, as of September 2026. The page lists two tablet strengths, and its structured data carries a single low and high price, so the same figure applies to either.

Three details on that page matter as much as the number. First, the page says: "This is an out-of-pocket price." It is a cash price for people paying without insurance, not an insurance price, and the page tells insured readers to check their copay first because it may be lower. Second, the order does not go through a local pharmacy. In the page's own words, "AstraZeneca manages direct patient orders through AstraZeneca Direct. AstraZeneca Direct will guide you through eligibility and offers delivery options." Third, the page's structured data carries a price-valid-until date of September 29, 2026, and its "Last updated" field reads "unavailable", so the figure should be re-read on the page itself before anyone relies on it.

The same page states "Generic alternative available" and links to a TrumpRx listing for dapagliflozin propanediol, the generic. That listing works differently: it shows coupon prices at pharmacies near a ZIP code rather than a single manufacturer price, and it warns, "Prices may vary depending on what the pharmacy has in stock. Call to confirm the final price." Its page description reads "Starting at $8.00" for the generic as of September 2026, a floor for the search results, not a promise for any one pharmacy.

Is there a generic for Farxiga?

Yes, by FDA record, although a "generic Farxiga" is approved under the ingredient name dapagliflozin rather than the brand name. The Drugs@FDA database, read through the openFDA API on September 22, 2026, returns 21 applications for dapagliflozin. Two are AstraZeneca's original new drug applications, for Farxiga tablets and for the Xigduo XR combination. The other 19 are abbreviated new drug applications (ANDAs), the pathway for generics, and every one of the 19 shows an original submission with status "AP" (approved) dated 2026-04-06 in the record. Thirteen of those ANDAs are for dapagliflozin tablets on their own, from sponsors including Teva, Sandoz, Lupin, Cipla, Zydus, Aurobindo, Alembic, Alkem, Macleods, MSN, Biocon, Aizant and Inventia. The remaining six are combination tablets that pair dapagliflozin with metformin or with saxagliptin.

An approval record is not a shelf. Drugs@FDA shows that FDA has approved these products; it does not show which are being shipped, which pharmacies stock them, or what they cost. The TrumpRx generic listing described above is, as of September 2026, the only government page found that prints any generic dapagliflozin figure, and it presents that figure as a pharmacy-by-pharmacy coupon price. For a plain-language look at how generic approval works in another drug class, see is there a generic Zepbound.

What is the Medicare negotiated price for Farxiga?

Farxiga was one of the ten Part D drugs in the first cycle of the Medicare Drug Price Negotiation Program, created by the Inflation Reduction Act. The CMS fact sheet on negotiated prices for initial price applicability year 2026 lists Farxiga, made by AstraZeneca AB, for "Diabetes; Heart failure; Chronic kidney disease", with a negotiated price of $178.50 for a 30-day supply against a 2023 list price of $556.00, as of September 2026. The fact sheet describes these as "negotiated prices, which the statute refers to as Maximum Fair Prices (MFPs), for 10 drugs covered under Medicare Part D that will go into effect beginning January 1, 2026."

CMS also publishes a data file of selected drugs and their maximum fair prices. The version dated May 26, 2026 lists Farxiga's $178.50 price with an end date of December 31, 2026, and a second row marked "Inflation adjustment" at $183.33 effective January 1, 2027, as of September 2026. CMS explains that the file "contains the single negotiated price for a 30-day equivalent supply of each selected drug."

The MFP is the price negotiated between CMS and the manufacturer for what Medicare Part D covers. It is not the amount a person hands the pharmacist, which depends on the plan's cost-sharing rules; a Part D plan or Medicare itself can say what applies to a specific enrollee. CMS's own program page also notes that a selected drug can be removed from the program once FDA approves a generic and it is marketed, so the generic approvals above may change Farxiga's status in future years; the current CMS file still lists Farxiga.

Does AstraZeneca offer a savings card for Farxiga?

Yes. The savings and insurance support page on farxiga.com, read live on September 22, 2026, offers a downloadable Farxiga savings card and says that eligible commercially insured patients can get brand-name Farxiga "for as low as $0" a month, "Subject to eligibility and monthly savings limit", as of September 2026. The page states plainly: "Not available for government-insured patients." That excludes Medicare, Medicaid and similar coverage, which is why the Medicare negotiated price and the manufacturer card describe two different groups of people.

The same page describes a mail-order rebate: download a rebate form, attach the original mail-order receipt and mail it in, repeating the step with each refill. It lists a savings phone line for questions about eligibility. Terms of manufacturer programs change, so the current terms on the manufacturer's page govern.

What is Farxiga approved for?

The current Farxiga prescribing information from AstraZeneca Pharmaceuticals LP (version 49, effective June 2026, read through openFDA) lists four indications, grouped here by category:

• Chronic kidney disease: to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.
• Heart failure: to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visits in adults with heart failure.
• Type 2 diabetes with cardiovascular risk: to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors.
• Glycemic control: "As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus."

The label's Limitations of Use say Farxiga is not recommended to improve glycemic control in type 1 diabetes, is not recommended for glycemic control below a stated kidney-function threshold, and is not recommended for chronic kidney disease in people with polycystic kidney disease or recent immunosuppressive therapy for kidney disease. Weight management does not appear anywhere in the indications. Our guide to how to read a prescription label explains where each of these sections sits.

What determines what you actually pay?

The published numbers above bracket the Farxiga price range; five things decide where an individual lands.

1. Insurance formulary tier. Plans place Farxiga on a tier, and the tier sets the copay or coinsurance. Now that generic dapagliflozin is FDA-approved, some plans may prefer the generic and set a higher share for the brand.
2. Deductible stage. Before a deductible is met, a plan may pass the full negotiated pharmacy price to the patient; after it, the copay applies.
3. Brand versus generic. The prescriber writes the product, and state substitution rules and the plan decide whether a generic is dispensed. Ask the pharmacist which product is being filled and what each would cost. The manufacturer's own site, read on September 22, 2026, states "FARXIGA is now available in a generic form!" and tells patients who want the brand to ask their doctor to indicate "DAW" (Dispense as Written) on the prescription.
4. Pharmacy and channel. The TrumpRx brand price goes through AstraZeneca Direct; the TrumpRx generic listing is a coupon at local pharmacies; a plan's mail-order pharmacy may price differently again.
5. Program eligibility. The manufacturer card is for commercially insured patients only. The Medicare MFP applies through Part D. TrumpRx is a cash channel. A person usually fits one of these, not all three.

Cost questions in this drug class rhyme with those in the GLP-1 class, where list prices, manufacturer programs and government pages also diverge; how much Wegovy costs walks through that example.

Does Farxiga cause weight loss?

People search for "Farxiga weight loss" often enough that the question deserves a direct answer: Farxiga is not FDA-approved for weight management, and its label does not describe it as a weight-loss medicine. Body weight appears in the Clinical Studies section of the label, where trials run to study blood sugar in type 2 diabetes recorded weight as a measured outcome. The label reports, in qualitative terms, that some study arms showed a "statistically significant reduction in body weight" compared with certain comparators; the label's figures are left out here because they come from diabetes trials, not from a weight-management study, and quoting them would imply an approval that does not exist.

An observation in a clinical studies section is not an indication. Whether an SGLT2 inhibitor is appropriate for a given person is a prescribing decision that belongs to a licensed physician, made against the label's approved uses, warnings and the person's own history. This article does not recommend or explain how to obtain Farxiga for weight loss. The same class question, read from the label of the other widely searched SGLT2 inhibitor, is covered in Jardiance and weight loss. Readers looking for products that do carry an FDA weight-management indication can start with what a GLP-1 medication is.

Questions to bring to a physician or pharmacist

• Is my prescription for brand Farxiga or generic dapagliflozin, and what does each cost under my plan today?
• Which tier is it on, and am I still in my deductible?
• If I have commercial insurance, do I qualify for the manufacturer savings card, and what is the monthly limit?
• If I have Medicare Part D, how does the negotiated price show up in my plan's cost-sharing?
• If I pay cash, what is the TrumpRx price today, and does AstraZeneca Direct ship to my state?
• Which of the label's four indications applies to me, and which warnings should I know about?

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Prices and label text were read from the government and manufacturer pages named above on September 22, 2026; they change, and the live pages govern.